
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
GENSIGHT BIOLOG. EO -,025 G49N FR0013183985 BAW/UFN
© 2024 Xetra Newsboard
Realtime | Geld | Brief | Zeit |
---|---|---|---|
0,227 | 0,234 | 22:11 | |
0,227 | 0,234 | 22:00 |
Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
19.03. | GenSight Biologics Confirms Definitive Full-Year 2024 Consolidated Financial Results Are in Line with Estimates | Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal... ► Artikel lesen | |
17.03. | GenSight Biologics Announces LUMEVOQ Scientific Updates at NANOS 2025 | Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative... ► Artikel lesen | |
07.03. | GenSight Biologics Announces Financing Amounting to c. €0.9 Million from Existing Investors | Regulatory News:
This press release is not being made in and copies of It may not be distributed or sent, directly or indirectly, into the United States, Canada, South Africa, Japan or Australia
GenSight... ► Artikel lesen | |
28.02. | GenSight Biologics S.A. reports FY results | ||
27.02. | GenSight Biologics S.A.: GenSight Biologics Reports Estimated Full-Year 2024 Consolidated Financial Results |
Review of LUMEVOQ® dossier to resume compassionate access program in France is ongoing; in parallel, work continues on the new RECOVER Phase III clinical trial and marketing application to the... ► Artikel lesen |